{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:15:50Z","timestamp":1790648150400,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucocorticoids are a mainstay in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). The glucocorticoid receptor (GR), a ligand-activated transcription factor (TF), mediates their actions. Chromatin occupancy, chromatin-protein networks (chromatomes) and gene programmes of GR are regulated by SUMOylation, a post-translational modification with therapeutic implications in other hematomalignancies. To unravel the GR-SUMOylation crosstalk in B-ALL, we induced hypoSUMOylation in NALM6 B-ALL cells with a SUMOylation inhibitor (SUMOi, ML-792). Genome-wide profiling of GR and SUMO chromatin-binding and chromatin accessibility revealed that hypoSUMOylation augmented GR chromatin occupancy and altered chromatin openness. Association with transcriptome data indicated that the hypoSUMOylation-induced GR-binding sites predominantly repressed genes associated with cell cycle and DNA replication. Consistently, hypoSUMOylation potentiated glucocorticoid-induced cell cycle arrest and growth suppression. Moreover, our proteomic analyses revealed that the protein network of chromatin-bound GR is tightly intertwined with SUMO2\/3 and that SUMOylation modulates the stability of the network. The chromatome contained several B-cell TFs with cognate binding motifs found on GR-adjacent chromatin sites, indicating their simultaneous occupancy on chromatin. In sum, our data imply potential for targeting SUMOylation to increase sensitivity to glucocorticoids in B-ALL, supported by ex vivo data of glucocorticoid and SUMOi TAK-981 combination-treated B-ALL patient samples.<\/jats:p>","DOI":"10.1038\/s41388-025-03305-3","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T13:52:13Z","timestamp":1739541133000},"page":"1259-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["SUMOylation inhibition potentiates the glucocorticoid receptor to program growth arrest of acute lymphoblastic leukemia cells"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0755-9532","authenticated-orcid":false,"given":"Emma","family":"Valima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7783-4473","authenticated-orcid":false,"given":"Vera","family":"Varis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kseniia","family":"Bureiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6100-5815","authenticated-orcid":false,"given":"Joanna K.","family":"Lempi\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Mari","family":"Schroderus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4468-9877","authenticated-orcid":false,"given":"Laura","family":"Oksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-0797","authenticated-orcid":false,"given":"Olli","family":"Lohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuure","family":"Kinnunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1340-9732","authenticated-orcid":false,"given":"Markku","family":"Varjosalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9471-7026","authenticated-orcid":false,"given":"Einari A.","family":"Niskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-1436","authenticated-orcid":false,"given":"Ville","family":"Paakinaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2373-0578","authenticated-orcid":false,"given":"Jorma J.","family":"Palvimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"3305_CR1","unstructured":"SEER. Childhood Leukemia - Cancer Stat Facts. 2023. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/childleuk.html."},{"key":"3305_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.","journal-title":"Blood Cancer J"},{"key":"3305_CR3","doi-asserted-by":"crossref","unstructured":"Mengxuan S, Fen Z, Runming J. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era. Front Pediatrics. 2022;10. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.923419.","DOI":"10.3389\/fped.2022.923419"},{"key":"3305_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","volume":"11","author":"H Inaba","year":"2010","unstructured":"Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukemia: comparison of prednisone and dexamethasone. Lancet Oncol. 2010;11:1096\u2013106.","journal-title":"Lancet Oncol"},{"key":"3305_CR5","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","volume":"91","author":"S Paul","year":"2016","unstructured":"Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016;91:1645\u201366.","journal-title":"Mayo Clin Proc"},{"key":"3305_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","volume":"94","author":"M D\u00f6rdelmann","year":"1999","unstructured":"D\u00f6rdelmann M, Reiter A, Borkhardt A, Ludwig WD, G\u00f6tz N, Viehmann S, et al. Prednisone Response Is the Strongest Predictor of Treatment Outcome in Infant Acute Lymphoblastic Leukemia. Blood. 1999;94:1209\u201317.","journal-title":"Blood"},{"key":"3305_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ccell.2018.11.011","volume":"34","author":"JA Brown","year":"2018","unstructured":"Brown JA, Ferrando A. Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally. Cancer Cell. 2018;34:869\u201371.","journal-title":"Cancer Cell"},{"key":"3305_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6123(10)82001-1","volume":"182","author":"LK Smith","year":"2010","unstructured":"Smith LK, Cidlowski JA. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. Prog Brain Res. 2010;182:1\u201330.","journal-title":"Prog Brain Res"},{"key":"3305_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood-2014-05-576470","volume":"125","author":"D Jing","year":"2015","unstructured":"Jing D, Bhadri VA, Beck D, Thoms JAI, Yakob NA, Wong JWH, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2015;125:273\u201383.","journal-title":"Blood"},{"key":"3305_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc.2016.143","volume":"17","author":"JS Seeler","year":"2017","unstructured":"Seeler JS, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017;17:184\u201397.","journal-title":"Nat Rev Cancer"},{"key":"3305_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/ncb1717","volume":"10","author":"V Lallemand-Breitenbach","year":"2008","unstructured":"Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML\u2013RAR\u03b1 through a SUMO-triggered RNF4\/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10:547\u201355.","journal-title":"Nat Cell Biol"},{"key":"3305_CR12","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.celrep.2014.05.016","volume":"7","author":"G Bossis","year":"2014","unstructured":"Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, et al. The ROS\/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. Cell Rep. 2014;7:1815\u201323.","journal-title":"Cell Rep"},{"key":"3305_CR13","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1158\/0008-5472.CAN-17-3361","volume":"78","author":"H Baik","year":"2018","unstructured":"Baik H, Boulanger M, Hosseini M, Kowalczyk J, Zaghdoudi S, Salem T, et al. Targeting the SUMO Pathway Primes All- trans Retinoic Acid\u2013Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. Cancer Res. 2018;78:2601\u201313.","journal-title":"Cancer Res"},{"key":"3305_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.bbrc.2019.04.079","volume":"513","author":"P Zhou","year":"2019","unstructured":"Zhou P, Chen X, Li M, Tan J, Zhang Y, Yuan W, et al. 2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. Biochem Biophys Res Commun. 2019;513:1063\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"3305_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.molcel.2018.07.027","volume":"71","author":"X Zhao","year":"2018","unstructured":"Zhao X. SUMO-Mediated Regulation of Nuclear Functions and Signaling Processes. Mol Cell. 2018;71:409\u201318.","journal-title":"Mol Cell"},{"key":"3305_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41580-022-00500-y","volume":"23","author":"ACO Vertegaal","year":"2022","unstructured":"Vertegaal ACO. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 2022;23:715\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3305_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/nar\/gkt1033","volume":"42","author":"V Paakinaho","year":"2014","unstructured":"Paakinaho V, Kaikkonen S, Makkonen H, Benes V, Palvimo JJ. SUMOylation regulates the chromatin occupancy and anti-proliferative gene programs of glucocorticoid receptor. Nucleic Acids Res. 2014;42:1575\u201392.","journal-title":"Nucleic Acids Res"},{"key":"3305_CR18","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/nar\/gkab032","volume":"49","author":"V Paakinaho","year":"2021","unstructured":"Paakinaho V, Lempi\u00e4inen JK, Sigismondo G, Niskanen EA, Malinen M, J\u00e4\u00e4skel\u00e4inen T, et al. SUMOylation regulates the protein network and chromatin accessibility at glucocorticoid receptor-binding sites. Nucleic Acids Res. 2021;49:1951\u201371.","journal-title":"Nucleic Acids Res"},{"key":"3305_CR19","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1101\/gad.1214604","volume":"18","author":"G Gill","year":"2004","unstructured":"Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev. 2004;18:2046\u201359.","journal-title":"Genes Dev"},{"key":"3305_CR20","doi-asserted-by":"publisher","first-page":"35368","DOI":"10.1074\/jbc.M104214200","volume":"276","author":"MH Tatham","year":"2001","unstructured":"Tatham MH, Jaffray E, Vaughan OA, Desterro JMP, Botting CH, Naismith JH, et al. Polymeric Chains of SUMO-2 and SUMO-3 Are Conjugated to Protein Substrates by SAE1\/SAE2 and Ubc9. J Biol Chem. 2001;276:35368\u201374.","journal-title":"J Biol Chem"},{"key":"3305_CR21","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1091\/mbc.E21-01-0031","volume":"32","author":"D Bouchard","year":"2021","unstructured":"Bouchard D, Wang W, Yang WC, He S, Garcia A, Matunis MJ. SUMO paralogue-specific functions revealed through systematic analysis of human knockout cell lines and gene expression data. Mol Biol Cell. 2021;32:1849\u201366.","journal-title":"Mol Biol Cell"},{"key":"3305_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1096\/fj.09-136259","volume":"24","author":"SJL van Wijk","year":"2010","unstructured":"van Wijk SJL, Timmers HTM. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J. 2010;24:981\u201393.","journal-title":"FASEB J"},{"key":"3305_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.tibs.2007.05.002","volume":"32","author":"D Mukhopadhyay","year":"2007","unstructured":"Mukhopadhyay D, Dasso M. Modification in reverse: the SUMO proteases. Trends Biochemical Sci. 2007;32:286\u201395.","journal-title":"Trends Biochemical Sci"},{"key":"3305_CR24","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/bloodadvances.2022007956","volume":"7","author":"HS Kim","year":"2023","unstructured":"Kim HS, Kim BR, Dao TTP, Kim JM, Kim YJ, Son H, et al. TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently. Blood Adv. 2023;7:3155\u201368.","journal-title":"Blood Adv"},{"key":"3305_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.stem.2018.10.001","volume":"23","author":"JC Cossec","year":"2018","unstructured":"Cossec JC, Theurillat I, Chica C, B\u00faa Agu\u00edn S, Gaume X, Andrieux A, et al. SUMO Safeguards Somatic and Pluripotent Cell Identities by Enforcing Distinct Chromatin States. Cell Stem Cell. 2018;23:742\u201357.e8.","journal-title":"Cell Stem Cell"},{"key":"3305_CR26","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1182\/blood-2014-06-584524","volume":"124","author":"A Hoellein","year":"2014","unstructured":"Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, et al. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014;124:2081\u201390.","journal-title":"Blood"},{"key":"3305_CR27","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2009-03-211045","volume":"115","author":"JJ Driscoll","year":"2010","unstructured":"Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010;115:2827\u201334.","journal-title":"Blood"},{"key":"3305_CR28","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1073\/pnas.1816254116","volume":"116","author":"C Poulard","year":"2019","unstructured":"Poulard C, Kim HN, Fang M, Kruth K, Gagnieux C, Gerke DS, et al. Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2019;116:3052\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3305_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"3305_CR30","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nchembio.2463","volume":"13","author":"X He","year":"2017","unstructured":"He X, Riceberg J, Soucy T, Koenig E, Minissale J, Gallery M, et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 2017;13:1164\u201371.","journal-title":"Nat Chem Biol"},{"key":"3305_CR31","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1182\/blood-2017-02-766204","volume":"129","author":"KA Kruth","year":"2017","unstructured":"Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, et al. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood. 2017;129:3000\u20138.","journal-title":"Blood"},{"key":"3305_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","volume":"135","author":"B Li","year":"2020","unstructured":"Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135:41\u201355.","journal-title":"Blood"},{"key":"3305_CR33","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/0008-5472.CAN-06-4244","volume":"67","author":"PS Bachmann","year":"2007","unstructured":"Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, Kees UR, et al. Divergent Mechanisms of Glucocorticoid Resistance in Experimental Models of Pediatric Acute Lymphoblastic Leukemia. Cancer Res. 2007;67:4482\u201390.","journal-title":"Cancer Res"},{"key":"3305_CR34","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1128\/MCB.00062-12","volume":"32","author":"TE Reddy","year":"2012","unstructured":"Reddy TE, Gertz J, Crawford GE, Garabedian MJ, Myers RM. The hypersensitive glucocorticoid response specifically regulates period 1 and expression of circadian genes. Mol Cell Biol. 2012;32:3756\u201367.","journal-title":"Mol Cell Biol"},{"key":"3305_CR35","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","volume":"64","author":"SP Langston","year":"2021","unstructured":"Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, et al. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. J Med Chem. 2021;64:2501\u201320.","journal-title":"J Med Chem"},{"key":"3305_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-021-02226-9","volume":"41","author":"L Du","year":"2022","unstructured":"Du L, Liu W, Aldana-Masangkay G, Pozhitkov A, Pichiorri F, Chen Y, et al. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. J Exp Clin Cancer Res. 2022;41:8.","journal-title":"J Exp Clin Cancer Res"},{"key":"3305_CR37","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41375-023-01838-8","volume":"37","author":"JS Kroonen","year":"2023","unstructured":"Kroonen JS, de Graaf IJ, Kumar S, Remst DFG, Wouters AK, Heemskerk MHM, et al. Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies. Leukemia. 2023;37:864\u201376.","journal-title":"Leukemia"},{"key":"3305_CR38","doi-asserted-by":"publisher","first-page":"gkae653","DOI":"10.1093\/nar\/gkae653","volume":"52","author":"KM Launonen","year":"2024","unstructured":"Launonen KM, Varis V, Aaltonen N, Niskanen EA, Varjosalo M, Paakinaho V, et al. Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells. Nucleic Acids Res. 2024;52:gkae653.","journal-title":"Nucleic Acids Res"},{"key":"3305_CR39","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1038\/nprot.2013.150","volume":"8","author":"S Wang","year":"2013","unstructured":"Wang S, Sun H, Ma J, Zang C, Wang C, Wang J, et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat Protoc. 2013;8:2502\u201315.","journal-title":"Nat Protoc"},{"key":"3305_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"3305_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235\u20139.","journal-title":"Nature"},{"key":"3305_CR42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature21076","volume":"542","author":"LN Chan","year":"2017","unstructured":"Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479\u201383.","journal-title":"Nature"},{"key":"3305_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.celrep.2019.08.088","volume":"29","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Nataraj NB, Sekar A, Ghosh S, Bornstein C, Drago-Garcia D, et al. ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell Rep. 2019;29:104\u201317.e4.","journal-title":"Cell Rep"},{"key":"3305_CR44","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nm.3216","volume":"19","author":"Y Chen","year":"2013","unstructured":"Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 2013;19:1023\u20139.","journal-title":"Nat Med"},{"key":"3305_CR45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/leu.2012.293","volume":"27","author":"E Tijchon","year":"2013","unstructured":"Tijchon E, Havinga J, van Leeuwen FN, Scheijen B. B-lineage transcription factors and cooperating gene lesions required for leukemia development. Leukemia. 2013;27:541\u201352.","journal-title":"Leukemia"},{"key":"3305_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2024.100741","volume":"23","author":"L Van Moortel","year":"2024","unstructured":"Van Moortel L, Verhee A, Thommis J, Houtman R, Melchers D, Delhaye L, et al. Selective Modulation of the Human Glucocorticoid Receptor Compromises GR Chromatin Occupancy and Recruitment of p300\/CBP and the Mediator Complex. Mol Cell Proteom. 2024;23:100741.","journal-title":"Mol Cell Proteom"},{"key":"3305_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC. What is synergy? Pharm Rev. 1989;41:93\u2013141.","journal-title":"Pharm Rev"},{"key":"3305_CR48","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. Genomics Proteom Bioinforma. 2022;20:587\u201396.","journal-title":"Genomics Proteom Bioinforma"},{"key":"3305_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3305_CR50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38:576\u201389.","journal-title":"Mol Cell"},{"key":"3305_CR51","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1038\/s41388-020-1153-3","volume":"39","author":"JK Lempi\u00e4inen","year":"2020","unstructured":"Lempi\u00e4inen JK, Manjur ABMK, Malinen M, Ketola K, Niskanen EA, Palvimo JJ. BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation. Oncogene. 2020;39:2391\u2013407.","journal-title":"Oncogene"},{"key":"3305_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1\u201313.","journal-title":"Nucleic Acids Res"},{"key":"3305_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/ng.759","volume":"43","author":"S John","year":"2011","unstructured":"John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet. 2011;43:264\u20138.","journal-title":"Nat Genet"},{"key":"3305_CR54","doi-asserted-by":"publisher","first-page":"21.29.1","DOI":"10.1002\/0471142727.mb2129s109","volume":"109","author":"J Buenrostro","year":"2015","unstructured":"Buenrostro J, Wu B, Chang H, Greenleaf W. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. Curr Protoc Mol Biol. 2015;109:21.29.1\u201321.29.9.","journal-title":"Curr Protoc Mol Biol"},{"key":"3305_CR55","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/nar\/gku1375","volume":"43","author":"S Toropainen","year":"2015","unstructured":"Toropainen S, Malinen M, Kaikkonen S, Rytinki M, J\u00e4\u00e4skel\u00e4inen T, Sahu B, et al. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res. 2015;43:848\u201361.","journal-title":"Nucleic Acids Res"},{"key":"3305_CR56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357\u20139.","journal-title":"Nat Methods"},{"key":"3305_CR57","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2016.020","volume":"11","author":"H Mohammed","year":"2016","unstructured":"Mohammed H, Taylor C, Brown GD, Papachristou EK, Carroll JS. D\u2019Santos CS. Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. Nat Protoc. 2016;11:316\u201326.","journal-title":"Nat Protoc"},{"key":"3305_CR58","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41596-020-0365-x","volume":"15","author":"X Liu","year":"2020","unstructured":"Liu X, Salokas K, Weldatsadik RG, Gawriyski L, Varjosalo M. Combined proximity labeling and affinity purification\u2212mass spectrometry workflow for mapping and visualizing protein interaction networks. Nat Protoc. 2020;15:3182\u2013211.","journal-title":"Nat Protoc"},{"key":"3305_CR59","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1074\/mcp.TIR118.000900","volume":"17","author":"F Meier","year":"2018","unstructured":"Meier F, Brunner AD, Koch S, Koch H, Lubeck M, Krause M, et al. Online Parallel Accumulation\u2013Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer*. Mol Cell Proteom. 2018;17:2534\u201345.","journal-title":"Mol Cell Proteom"},{"key":"3305_CR60","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1074\/mcp.TIR120.002048","volume":"19","author":"F Yu","year":"2020","unstructured":"Yu F, Haynes SE, Teo GC, Avtonomov DM, Polasky DA, Nesvizhskii AI. Fast Quantitative Analysis of timsTOF PASEF Data with MSFragger and IonQuant. Mol Cell Proteom. 2020;19:1575\u201385.","journal-title":"Mol Cell Proteom"},{"key":"3305_CR61","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41592-020-0912-y","volume":"17","author":"F da Veiga Leprevost","year":"2020","unstructured":"da Veiga Leprevost F, Haynes SE, Avtonomov DM, Chang HY, Shanmugam AK, Mellacheruvu D, et al. Philosopher: a versatile toolkit for shotgun proteomics data analysis. Nat Methods. 2020;17:869\u201370.","journal-title":"Nat Methods"},{"key":"3305_CR62","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2021","unstructured":"Perez-Riverol Y, Bai J, Bandla C, Garc\u00eda-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2021;50:D543\u201352.","journal-title":"Nucleic Acids Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03305-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:14:39Z","timestamp":1746177279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03305-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":62,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5,23]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03305-3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}